Description:
<jats:title>Abstract</jats:title><jats:sec><jats:label /><jats:p>Cryopyrin‐associated periodic syndrome (<jats:styled-content style="fixed-case">CAPS</jats:styled-content>) is caused by a mutation in the <jats:italic><jats:styled-content style="fixed-case">NLRP</jats:styled-content>3</jats:italic> gene encoding cryopyrin production. Overproduction of interleukin‐1 (<jats:styled-content style="fixed-case">IL</jats:styled-content>‐1) leads to symptoms that are associated with elevated inflammatory markers, including periodic fever and a rash. We provide a clinical overview of <jats:styled-content style="fixed-case">CAPS</jats:styled-content> in children, including three Finnish case studies.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>When <jats:styled-content style="fixed-case">CAPS</jats:styled-content> has been diagnosed, an <jats:styled-content style="fixed-case">IL</jats:styled-content>‐1 blockade with biological should be introduced to lessen the symptoms and to prevent the progression of organ damage.</jats:p></jats:sec>